Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14987893 | 0.81 | MAPK1 (1.00) | MAPK1TDP1ALDH1A1MAPTHPGD | |
| SCHEMBL24859006 | 0.79 | MAPK1 (0.57) | MAPK1TDP1ALDH1A1MAPTHPGD | |
| SCHEMBL7338043 | 0.78 | ALDH1A1 (0.52) | ALDH1A1MAPTHPGDNPSR1GLA | |
| SCHEMBL14987885 | 0.77 | ALDH1A1 (1.00) | MAPK1TDP1ALDH1A1MAPTHPGD | |
| SCHEMBL28490522 | 0.77 | TSHR (0.57) | ALDH1A1MAPTHPGDNPSR1GLA | |
| SCHEMBL24124576 | 0.76 | ALDH1A1 (0.65) | MAPK1ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL14987989 | 0.76 | ALDH1A1 (0.64) | MAPK1ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL4265804 | 0.76 | ALDH1A1 (0.57) | ALDH1A1MAPTHPGDNPSR1GLA | |
| SCHEMBL6728049 | 0.76 | MEN1 (0.48) | TDP1ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL14987970 | 0.75 | MAPK1 (0.74) | MAPK1TDP1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365329-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | Vassilatis, Demetrios K. (GR) | 2018-08-29 | — | — | EP | claimed |
| WO-2017068070-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2017-04-27 | — | — | WO | claimed |
| US-8455489-B2 | Substituted pyrimidine compositions and methods of use | EXELIXIS, INC. (US) | 2013-06-04 | — | — | US | claimed |
| US-20250152590-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2025-05-15 | — | — | US | disclosed |
| EP-4029857-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | Vassilatis, Demetrios K. (GR) | 2022-07-20 | — | — | EP | disclosed |
| US-20210186975-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2021-06-24 | — | — | US | disclosed |
| US-10946019-B2 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | VASSILATIS DEMETRIOS K (GR) | 2021-03-16 | — | — | US | disclosed |
| US-20180311243-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2018-11-01 | — | — | US | disclosed |
| EP-3365329-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | Vassilatis, Demetrios K. (GR) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068070-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | VASSILATIS DEMETRIOS K (GR) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152590-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NCOR1 | MAPK1 1693/4885TDP1 1871/4885ALDH1A1 1790/4885 |
| US-20210186975-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NR4A3 | MAPK1 1495/4885TDP1 1926/4885ALDH1A1 1716/4885 |
| US-10946019-B2 | Nurr1:RXR activating compounds for simultaneous treatment of symptoms and pathology of Parkinson's disease | NR4A2, NR0B1, NR4A3 | MAPK1 1495/4885TDP1 1926/4885ALDH1A1 1716/4885 |
| US-20180311243-A1 | NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE | NR4A2, NR0B1, NR4A3 | MAPK1 1495/4885TDP1 1926/4885ALDH1A1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.